Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

CTRM Stock: The News That Has Castor Maritime Sailing Higher Today

Today, Castor Maritime announced three charter agreements for its ships, leading retail investors to jump into CTRM stock in a big way.

Short Squeeze Stocks: SPRT, ATER and 3 Others Experts Think Are Ready to Pop

Here are five of the top short squeeze stocks experts think have the potential to actually squeeze based on specific factors.

LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soaring?

Today, some news of positive clinical trial results for one of aTry's leading drug candidates has sent LIFE stock surging.

7 Things to Know About BKSY Stock as BlackSky Starts Trading Today

Here's what investors may want to know about BlackSky and BKSY stock as the company marks its first day of public trading today.

Terra Price Predictions Surge as LUNA Becomes the No. 11 Crypto

Today, investors are becoming increasingly interested in where the experts think LUNA could be headed via their Terra price predictions.

What Is Going on With Red-Hot Lithium Americas (LAC) Stock Today?

Today, investors are piling into Lithium Americas and LAC stock on news that a judge has denied an injunction against the company's key mine.

ATOS Stock Holders Should Mark Their Calendars for Oct. 7

Today, investors in Atossa Pharmaceuticals and ATOS stock appear to be cheering a delayed shareholder vote on a stock issuance proposal.

APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today

Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results.

Dear ANY Stock Fans, Pay Attention to These 2 Big Stories

Today, investors in Sphere 3D are seeing selling pressure continue, despite two catalysts that could take ANY stock higher.

Sports Betting Stocks: PENN, CZR, DKNG Are Heating Up as the NFL Season Kicks Off

As we near kickoff for the inaugural game of the 2021-2022 NFL season, investors eye sports betting stocks as a way to play this excitement.